Ultragenyx Pharma (RARE) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Piper Jaffray Raises Price Target on Ultragenyx Pharma (RARE) to $82; Reiterates Overweight
August 9, 2016 8:53 AM EDTPiper Jaffray reiterated an Overweight rating on Ultragenyx Pharma (NASDAQ: RARE), and raised the price target to $82.00 (from $70.00), following the company's 2Q earnings report.
Analyst Steven Breazzano commented, "After the close, RARE reported 2Q earnings and provided an... More
